# OnCo record liposomal-irinotecan (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/liposomal-irinotecan/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "liposomal-irinotecan" ;
  schema:name "Liposomal irinotecan"@en ;
  schema:description "Irinotecan wrapped in a fat bubble so it circulates longer. It is approved for pancreatic cancer, and in bile duct and gallbladder cancer one Korean trial found it helped as second-line treatment while a German trial did not."@en ;
  schema:url <https://onco.cc/drugs/liposomal-irinotecan/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Irinotecan> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8b58efa-1820-48a4-b70d-62918fc4abfc>, <https://doi.org/10.1016/S1470-2045(21)00486-1>, <https://doi.org/10.1001/jamaoncol.2023.0016> ;
  onco:status "approved" ;
  onco:modality "Liposome-encapsulated topoisomerase I inhibitor (cytotoxic)" ;
  schema:alternateName "Onivyde" ;
  onco:approval "US 2015: Metastatic pancreatic adenocarcinoma after gemcitabine-based therapy, with fluorouracil and leucovorin (NAPOLI-1)", "EU 2016: Metastatic pancreatic adenocarcinoma after gemcitabine, with fluorouracil and leucovorin", "US 2024: First-line metastatic pancreatic adenocarcinoma in NALIRIFOX (NAPOLI 3)" ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:companies <https://onco.cc/companies/ipsen/>, <https://onco.cc/companies/servier/> ;
  onco:trials <https://onco.cc/trials/nifty/>, <https://onco.cc/trials/nife/>, <https://onco.cc/trials/naliricc/> .